BE637389A
(fr)
*
|
1962-09-13 |
|
|
|
GB1560274A
(en)
*
|
1977-02-28 |
1980-02-06 |
Ici Ltd |
Phenylbut 1-ene derivatives having antiostrogenicactivity
|
EP0002097B1
(fr)
|
1977-08-22 |
1981-08-05 |
Imperial Chemical Industries Plc |
Dérivés de triphénylalcène, procédé pour leur préparation et compositions pharmaceutiques les contenant
|
US4206234A
(en)
*
|
1977-08-22 |
1980-06-03 |
Imperial Chemical Industries Limited |
Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
|
HU178253B
(en)
*
|
1979-08-15 |
1982-04-28 |
Gyogyszerkutato Intezet |
Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
|
DE3046719C2
(de)
*
|
1980-12-11 |
1983-02-17 |
Klinge Pharma GmbH, 8000 München |
1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
|
EP0127128B1
(fr)
*
|
1983-05-24 |
1987-02-25 |
Bristol-Myers Company |
Procédé de conversion d'isomère E de 1,2-diphényl-1-[4-(2-diméthylaminoéthoxy)-phényl]-1-butène en chlorhydrate de tamoxifen
|
US4806685A
(en)
*
|
1985-08-05 |
1989-02-21 |
Gyogyszerkutato Inteezet/Pharmaceutical Research Institute |
1,1,2-triphenylpropane and -propene derivatives
|
GB8604528D0
(en)
*
|
1986-02-24 |
1986-04-03 |
Ici Plc |
Therapeutic agents
|
CA1289570C
(fr)
*
|
1986-06-16 |
1991-09-24 |
Tetsuji Asao |
Derives 1,1,2-triaryl-1-alcenes
|
EP0287690B1
(fr)
*
|
1987-04-21 |
1992-09-02 |
HEUMANN PHARMA GMBH & CO |
Adducts stables de solvant avec Z-1-(p-bêta-diméthylamino-éthoxyphényl)-1-(p-hydroxyphényl)-2-phénylbut-1-ène
|
DE3736682A1
(de)
*
|
1987-10-29 |
1989-05-11 |
Klinge Co Chem Pharm Fab |
Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5446203A
(en)
*
|
1992-08-25 |
1995-08-29 |
New York University |
Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
|
US6251920B1
(en)
|
1993-05-13 |
2001-06-26 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
US5770609A
(en)
*
|
1993-01-28 |
1998-06-23 |
Neorx Corporation |
Prevention and treatment of cardiovascular pathologies
|
US5354861A
(en)
*
|
1992-11-04 |
1994-10-11 |
National University Of Singapore |
2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
ATE406909T1
(de)
*
|
1993-05-13 |
2008-09-15 |
Poniard Pharmaceuticals Inc |
Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
|
WO1996040098A2
(fr)
|
1995-06-07 |
1996-12-19 |
Neorx Corporation |
Prevention et traitement de pathologies cardio-vasculaires au moyen d'analogues de tamoxifene
|
ES2105525T3
(es)
*
|
1993-06-24 |
1997-10-16 |
Lilly Co Eli |
2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
|
US5534526A
(en)
*
|
1993-12-21 |
1996-07-09 |
Eli Lilly And Company |
Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
|
US5462950A
(en)
*
|
1993-12-21 |
1995-10-31 |
Eli Lilly And Company |
Methods of treating menstrual symptoms and compositions therefore
|
US6417198B1
(en)
*
|
1993-12-21 |
2002-07-09 |
Eli Lilly And Company |
Methods of inhibiting CNS problems in post-menopausal women
|
US5451590A
(en)
*
|
1993-12-21 |
1995-09-19 |
Eli Lilly & Co. |
Methods of inhibiting sexual precocity
|
GB9326255D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Roussel Lab Ltd |
Medical device for the prevention and treatment of cancer
|
US5650425A
(en)
*
|
1994-04-04 |
1997-07-22 |
Pharmos Corporation |
Permanently ionic derivatives of steroid hormones and their antagonists
|
US5681835A
(en)
*
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
NZ272608A
(en)
|
1994-07-22 |
2000-05-26 |
Lilly Co Eli |
Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
|
DE19526146A1
(de)
*
|
1995-07-07 |
1997-01-09 |
Schering Ag |
Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
|
HUP9900951A3
(en)
|
1996-01-20 |
2000-02-28 |
Bradford University Bradford |
Process for producing tamoxifen and analogues thereof
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
JP2001511182A
(ja)
*
|
1997-02-09 |
2001-08-07 |
ファーモス コーポレイション |
ステロイドホルモンの永久に荷電された誘導体の増進された抗血管形成誘導活性
|
US6083990A
(en)
*
|
1997-04-02 |
2000-07-04 |
Pharmos Corporation |
Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
|
WO1998037892A1
(fr)
*
|
1997-02-27 |
1998-09-03 |
Pharmacia & Upjohn Company |
Therapie au tamoxifene visant a attenuer une diarrhee declenchee par le chlorhydrate d'irinotecan
|
GB9715479D0
(en)
*
|
1997-07-23 |
1997-10-01 |
Univ Bradford |
Tamoxifen and analogues thereof
|
UA70925C2
(uk)
|
1997-08-15 |
2004-11-15 |
Дюк Юнівесіті |
Спосіб лікування естрогенстимульованого раку
|
TW593256B
(en)
|
1999-11-16 |
2004-06-21 |
Hormos Medical Oy Ltd |
Triphenylalkene derivatives and their use as selective estrogen receptor modulators
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
GB0012291D0
(en)
*
|
2000-05-23 |
2000-07-12 |
Astrazeneca Ab |
Pharmaceutical combination
|
US6613083B2
(en)
|
2001-05-02 |
2003-09-02 |
Eckhard Alt |
Stent device and method
|
CA2479665C
(fr)
*
|
2002-03-20 |
2011-08-30 |
Elan Pharma International Ltd. |
Compositions nanoparticulaires d'inhibiteurs d'angiogenese
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
US7332525B2
(en)
*
|
2003-01-17 |
2008-02-19 |
Castle Erik P |
Method of treatment of prostate cancer and composition for treatment thereof
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
EP1667692A1
(fr)
*
|
2003-09-19 |
2006-06-14 |
Pfizer Products Inc. |
Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste/antagoniste des oestrogenes
|
CA2546601A1
(fr)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Nouvelles substances thyromimetiques contenant du phosphore
|
EP3006039B1
(fr)
|
2004-03-02 |
2021-01-06 |
Acceleron Pharma Inc. |
Alk7 polypeptides pour stimuler la perte de graisse
|
US20050203086A1
(en)
*
|
2004-03-04 |
2005-09-15 |
Pfizer Inc. |
Methods of treatment using an EP2 selective receptor agonist
|
AU2005308575A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Warner-Lambert Company Llc |
7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
EP1906948A4
(fr)
|
2005-07-18 |
2010-03-17 |
Bipar Sciences Inc |
Traitement du cancer
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CA2652783C
(fr)
|
2006-05-22 |
2015-07-14 |
Hormos Medical Ltd. |
Procede de traitement d'une prostatite chronique non bacterienne par des modulateurs selectifs des recepteurs des oestrogenes ou par des inhibiteurs de l'aromatase
|
JP5193196B2
(ja)
|
2006-06-02 |
2013-05-08 |
ペア ツリー ウーマンズ ヘルス ケア |
萎縮性膣炎の治療の方法
|
US20100160442A1
(en)
*
|
2006-07-18 |
2010-06-24 |
Ossovskaya Valeria S |
Formulations for cancer treatment
|
EP2073807A1
(fr)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008070496A2
(fr)
|
2006-12-01 |
2008-06-12 |
Bristol-Myers Squibb Company |
Inhibiteurs d'amino cetp étendus
|
RS55735B1
(sr)
|
2007-08-03 |
2017-07-31 |
Summit (Oxford) Ltd |
Kombinacije lekova za lečenje dišenove mišićne distrofije
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
UA96076C2
(en)
|
2007-10-16 |
2011-09-26 |
Репрос Терапьютикс Инк. |
Use of trans-clomiphene
|
WO2010093601A1
(fr)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Nouveaux thyromimetiques contenant de l'acide sulfonique et methodes d'utilisation associees
|
BR112014017985A8
(pt)
|
2012-01-31 |
2017-07-11 |
Novartis Ag |
Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
|
JP2015508825A
(ja)
|
2012-02-29 |
2015-03-23 |
レプロス セラピューティクス インコーポレイティド |
アンドロゲン欠乏症を治療するための併用療法
|
EP2822955B1
(fr)
|
2012-03-05 |
2017-07-26 |
Xavier University |
Promédicaments de 4-hydroxytamoxifène et d'endoxifène à base de bore utilisés comme traitement pour le cancer du sein
|
CN103992234B
(zh)
*
|
2014-06-11 |
2016-05-18 |
扬子江药业集团江苏海慈生物药业有限公司 |
一种枸橼酸他莫昔芬e异构体的制备方法
|
US11633382B2
(en)
|
2015-11-10 |
2023-04-25 |
Paracrine Therapeutics Ab |
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
|
US20190183870A1
(en)
|
2016-01-05 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
WO2017136342A1
(fr)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant induisant la lyse cytotoxique à médiation immunitaire des cellules cancéreuses
|
CA3032153A1
(fr)
|
2016-08-19 |
2018-02-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulateurs selectifs du recepteur des oestrogenes (serms) conferant une protection contre la degenerescence des photorecepteurs
|
BR112020016256A2
(pt)
|
2018-02-21 |
2020-12-15 |
AI Therapeutics, Inc. |
Terapia de combinação com apilimod e agentes gluta-matérgicos
|
CN114514021A
(zh)
*
|
2019-06-10 |
2022-05-17 |
爱荷华大学研究基金会 |
用于治疗非酒精性脂肪性肝病、免疫缺陷、男性不育症和血管疾病的swell1调节剂
|
CN114133334A
(zh)
*
|
2021-11-09 |
2022-03-04 |
北京京丰制药(山东)有限公司 |
枸橼酸他莫昔芬的工业化制备工艺
|
EP4230196A1
(fr)
|
2022-02-21 |
2023-08-23 |
Som Innovation Biotech, S.A. |
Composés à utiliser dans le traitement des dystrophinopathies
|
EP4311546A1
(fr)
|
2022-07-26 |
2024-01-31 |
Dynacure |
Thérapie combinée pour myopathies
|